Novartis ESMO Event Presentation
PSMAfore study design
Eligible adults
Confirmed progressive mCRPC
≥ 1 PSMA-positive metastatic lesion on
68Ga-PSMA-11 PET/CT and no
exclusionary PSMA-negative lesions
Progressed once on prior
second-generation ARPI
• Candidates for change in ARPI
■ Taxane-naive (except [neo]adjuvant >
12 months ago)
-
Not candidates for PARP inhibition
ECOG performance status 0-1
11
NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION
177Lu-PSMA-617
7.4 GBq (200 mi) + 10%
Once every 6 weeks for 6 cycles
1:1
N = 468
Crossover allowed
upon centrally confirmed
radiographic progression
Safety
follow-up
Long-term
follow-up
Androgen receptor pathway inhibitor
(ARPI) change - abiraterone or enzalutamide
Randomization stratification factors
Prior ARPI setting (castration-resistant
vs. hormone-sensitive prostate cancer)
BPI-SF worst pain intensity score
(0-3 vs. >3)
NOVARTIS | Reimagining MedicineView entire presentation